by Peter Ciszewski | Dec 18, 2018
The FDA approved romiplostim for treatment of pediatric patients with immune thrombocytopenia. The approval of romiplostim (Nplate, Amgen) applies to children aged 1 year or older who have had immune thrombocytopenia (ITP) for at least 6 months and had insufficient...
by Peter Ciszewski | Dec 18, 2018
At the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, Aziz Nazha, MD of Cleveland Clinic sat down with CheckRare to provide an overview of myelodysplastic syndromes (MDS) — a group of blood disorders characterized by abnormal...
by Peter Ciszewski | Dec 17, 2018
A Phase 3 trial to investigate lenabasum as a potential treatment for dermatomyositis, a rare and often fatal multisystem inflammatory autoimmune disease affecting muscle and skin, have been initiated by Corbus Pharmaceuticals. The Phase 3 trial is called...
by Peter Ciszewski | Dec 17, 2018
Jennifer McNary, Rare Disease Advocate, explains why there is so much interest in Duchenne muscular dystrophy (DMD) and some of the future considerations for this rare disease. Duchenne muscular dystrophy is a progressive form of muscular dystrophy that occurs...
by Peter Ciszewski | Dec 16, 2018
Rod Humerickhouse, MD, PhD, asset strategy leader at AbbVie discusses some of the Venclexta (Venetoclax) data presented at this year’s 60th American Society of Hematology’s 2018 annual meeting in San Diego. Venclexta, combined with Vidaza, Dacogen or...
